Automated blood test strategy could spot hidden liver disease in routine checkups

NCT ID NCT07658755

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

LiverSeek is a study testing an automated screening program for advanced liver fibrosis in people aged 50-75 with risk factors like diabetes or obesity. When a routine blood test is done, the lab system automatically calculates a fibrosis score and, if needed, orders additional tests without the doctor having to act. The goal is to see how many high-risk patients have liver scarring and whether this approach can catch it early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

automated screening strategy using blood tests (FIB-4, ELF, MASEF) and nurse-led lifestyle intervention

What this could lead to

If successful, this could lead to a simple, automated way to catch liver fibrosis early in primary care, potentially preventing progression to severe liver disease.

What could go wrong

This is an observational screening study, not a treatment trial. It may not prove that early detection improves outcomes, and the lifestyle intervention sub-study is small.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fibrotic liver disease metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital General Universitario Gregorio Marañón

    RECRUITING

    Madrid, Madrid, 28007, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••